Vioxx Gains Six Months Pediatric Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck gains six months of pediatric exclusivity for its COX-2 inhibitor Vioxx (rofecoxib) with a supplemental NDA filing for juvenile rheumatoid arthritis, the company announced Feb. 27
You may also be interested in...
Merck's Vioxx Gains First-Line Juvenile Rheumatoid Arthritis Indication
FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).